Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 2, 2010

Phylogica Taps Isogenica’s In Vitro Display Technology

  • Australian-based biopharmaceutical company Phylogica will use Isogenica’s CIS display technology to optimize the performance of three of its lead compounds targeting CD40 ligand (CD40L). CD40L is a key protein involved in many inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.

    CIS display, an in vitro display technology, allows the generation of polypeptide libraries of unprecedented size and complexity, according to Isogenica. It is then possible to select polypeptides with high affinity and specificity for most targets, the company continues.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »